Working… Menu

Proton-Based Stereotactic Ablative Body Radiotherapy for Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03159676
Recruitment Status : Recruiting
First Posted : May 19, 2017
Last Update Posted : February 20, 2019
Information provided by (Responsible Party):
Thomas Pisansky, Mayo Clinic

Brief Summary:
Stereotactic ablative body radiotherapy (SABR), or stereotactic body radiotherapy (SBRT), is a specialized form of radiotherapy used to treat prostate cancer with five treatments over two weeks, compared with a conventional eight-week or longer treatment course. The purpose of this trial is to investigate the effect that proton-based SABR has on quality-of-life in patients with localized prostate cancer. The evaluation and treatment will otherwise follow standard of care, and is not considered investigational.

Condition or disease Intervention/treatment
Prostate Cancer Radiation: Proton beam

Detailed Description:
Patients with low-risk or intermediate-risk, clinically localized prostate cancer will be evaluated according to standard of care medical practices. The evaluation includes history and examination, prostate-specific antigen (PSA) blood testing, and review of the prior prostate biopsy pathology report; radiology scans (for example, computed tomography [CT], magnetic resonance imaging [MRI], radionuclide bone scan) may be done also; recently completed testing may not need to be repeated. Small markers will be placed in the prostate to guide the proton beam stereotactic ablative body radiotherapy (SABR) treatments, and a hydrogel spacer may also be placed between the prostate and the rectum to push the rectum away from the prostate; the hydrogel spacer will dissolve a few months later. Participants will receive five (5) proton SABR treatments over a two (2) week time period. The study will have participants complete a quality-of life questionnaire and be evaluated for side-effects before starting SABR, at the end of SABR, at three (3), six (6) and 12 months after SABR, and then yearly for five (5) years. Evaluation of the cancer status will follow standard of care practices for at least ten (10) years.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 150 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Proton-Based Stereotactic Ablative Body Radiotherapy (SABR) for Select Patients With Clinically Localized Prostate Cancer.
Actual Study Start Date : May 12, 2017
Estimated Primary Completion Date : June 2021
Estimated Study Completion Date : June 2029

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Intervention Details:
  • Radiation: Proton beam
    Proton beam
    Other Names:
    • Radiation therapy
    • Radiotherapy
    • Stereotactic ablative body radiotherapy
    • Stereotactic body radiotherapy
    • SABR
    • SBRT

Primary Outcome Measures :
  1. Incidence of late grade ≥3 Gastrointestinal and Renal and Urinary/Genitourinary adverse events at 24 months after SABR [ Time Frame: 24 months ]

Secondary Outcome Measures :
  1. Biochemical (PSA) failure [ Time Frame: 120 months ]
  2. Quality of life [ Time Frame: 60 months ]
    Patient-reported questionnaire

  3. Overall survival [ Time Frame: 120 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Sampling Method:   Non-Probability Sample
Study Population
Adult male patients with prostate cancer.

Inclusion Criteria:

  • Male, age ≥ 18 years.
  • Histological confirmation of adenocarcinoma of prostatic origin.
  • AJCC 7th edition clinical T1b-T2b.
  • AJCC clinical staging rules do not include findings from biopsy or imaging.
  • Gleason score ≤7 (International Society of Urological Pathologists grades 1-3).
  • Serum prostate-specific antigen ≤20 ng/mL.
  • Prostate-specific antigen <10 ng/mL, if dutasteride within last 90 days or finasteride within last 30 days.
  • Zubrod performance score 0-1.
  • Prostate volume <75-cc, determined by ultrasound, computed tomography or magnetic resonance imaging (modality with lesser volume is acceptable).
  • If neoadjuvant-concurrent androgen suppression is used, the prostate volume after the start of androgen suppression may be used.
  • American Urological Association voiding symptom index ≤15.
  • Ability to complete questionnaire(s) by themselves or with assistance.
  • Participation in a patient-reported outcomes survey program, inclusive of the Expanded Prostate Index Composite and CTCAE instruments.
  • Ability to provide informed written consent.

Exclusion Criteria:

  • Radiological- or pathologically-confirmed seminal vesicle invasion, lymph node involvement, or distant metastatic disease.
  • Radiological- or biopsy-confirmed extraprostatic tumor extension without AJCC 7th edition clinical T3a classification remain eligible.
  • Prior or anticipated external radiotherapy or brachytherapy, transurethral resection of the prostate, prostatic cryoablation/focused ultrasound/laser therapy, prostatectomy, or prostatic enucleation.
  • Prior bilateral orchiectomy, planned long-term (>6 months duration) androgen suppression or peripheral androgen blockade, or chemotherapy or immunotherapy for prostate cancer.
  • Prior hemi- or total hip arthroplasty.
  • Diabetes mellitus associated with vascular ulcers or wound healing problems, ulcerative colitis, connective tissue disorder, or chronic (≥120 days) warfarin use planned.
  • Co-morbid severe concurrent disease which, in the judgment of the investigator, would result in life expectancy <5 years.
  • Patients with a left cardiac ventricular assist device are ineligible.
  • Patients with an implanted medical electronic device (e.g., cardiac pacemaker) remain eligible if device monitoring complies with standard of practice (e.g., Cardiology and Medical Physics evaluation, function checks and during-treatment monitoring).
  • Immunocompromised due to HIV positive state.
  • Medical or psychiatric conditions that preclude informed decision-making or adherence.
  • Prior registration to an Institutional Review Board-approved therapeutic research study that includes proton beam therapy or photon-based radiotherapy (e.g., randomization to proton beam therapy vs. photon-based radiotherapy).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03159676

Layout table for location information
United States, Minnesota
Mayo Clinic in Rochester Recruiting
Rochester, Minnesota, United States, 55905
Contact: Clinical Trials Referral Office    855-776-0015   
Sponsors and Collaborators
Mayo Clinic

Additional Information:
Layout table for additonal information
Responsible Party: Thomas Pisansky, PI, Mayo Clinic Identifier: NCT03159676     History of Changes
Other Study ID Numbers: 17-000680
ROR1752 ( Other Identifier: Mayo Clinic )
First Posted: May 19, 2017    Key Record Dates
Last Update Posted: February 20, 2019
Last Verified: February 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Thomas Pisansky, Mayo Clinic:
Prostate cancer
Radiation therapy
Proton beam
Stereotactic ablative body radiotherapy
Stereotactic body radiotherapy
Low risk
Intermediate risk
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases